BUSINESSCNBC TOP
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics has acquired PolyPeptide Group in a $1.8 billion all-cash deal. The transaction is valued at 2.7 trillion won.
Related Signal
Adjacent reporting
- Ipsen is acquiring a Swiss biotech for up to $800 million to treat kidney transplant infections
- Incyte strikes up to $2bn deal for blood disorder biotech
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug